These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 15853471

  • 1. Interferon-beta1a treatment for multiple sclerosis.
    Sandberg-Wollheim M.
    Expert Rev Neurother; 2005 Jan; 5(1):25-34. PubMed ID: 15853471
    [Abstract] [Full Text] [Related]

  • 2. Interferon-beta1b for multiple sclerosis.
    Burks J.
    Expert Rev Neurother; 2005 Mar; 5(2):153-64. PubMed ID: 15853486
    [Abstract] [Full Text] [Related]

  • 3. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T, Bereczki D.
    Ideggyogy Sz; 2004 Nov 20; 57(11-12):401-16. PubMed ID: 15662768
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Treatment of multiple sclerosis with interferon beta 1b.
    Dhib-Jalbut S, McFarland HF.
    Baillieres Clin Neurol; 1997 Oct 20; 6(3):467-80. PubMed ID: 10101584
    [Abstract] [Full Text] [Related]

  • 6. [New approaches in research of therapy of multiple sclerosis].
    Hemmer B, Cepok S, Nessler S, Sommer N.
    Med Klin (Munich); 2001 Sep 15; 96 Suppl 1():23-8. PubMed ID: 11603112
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Neutralizing antibodies (NABS) and interferon beta-1b therapy of multiple sclerosis.
    Horowski R, Stürzebecher CS, Kapp JF.
    Funct Neurol; 2001 Sep 15; 16(2):117-28. PubMed ID: 11495417
    [No Abstract] [Full Text] [Related]

  • 9. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G, Barbarash O, Casset-Semanaz F, Jaber A, King J, Metz L, Pardo G, Simsarian J, Sørensen PS, Stubinski B, RNF Study Group.
    Clin Ther; 2007 Jun 15; 29(6):1128-45. PubMed ID: 17692727
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Early treatment.
    Comi G.
    Neurol Sci; 2006 Mar 15; 27 Suppl 1():S8-12. PubMed ID: 16708191
    [Abstract] [Full Text] [Related]

  • 13. Interferon after 10 years in patients with multiple sclerosis.
    Pozzilli C, Prosperini L, Sbardella E, Paolillo A.
    Neurol Sci; 2006 Sep 15; 27 Suppl 5():S369-72. PubMed ID: 16998723
    [Abstract] [Full Text] [Related]

  • 14. [A short history of beta-interferon therapy of multiple sclerosis].
    Stock G, Horowski R.
    Med Klin (Munich); 2001 Sep 15; 96 Suppl 1():3-9. PubMed ID: 11603113
    [Abstract] [Full Text] [Related]

  • 15. Interferon-beta1b in multiple sclerosis.
    Buttmann M, Rieckmann P.
    Expert Rev Neurother; 2007 Mar 15; 7(3):227-39. PubMed ID: 17341170
    [Abstract] [Full Text] [Related]

  • 16. [Rationale for an early treatment of multiple sclerosis].
    Comi G, Martino G.
    Rev Neurol; 2007 Mar 15; 30(12):1265-8. PubMed ID: 10935262
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis.
    Farrell R, Bendtzen K, Bertolotto A, Clark B, Comabella M, Deisenhammer F, Fogdell-Hahn A, Giovannoni G, Hartung HP, Hemmer B, Hillert J, Kappos L, Killestein J, Lindberg R, Montalban X, Polman C, Sorensen PS, European NABINMS Consortium.
    J Int Med Res; 2008 Mar 15; 36(1):204-8; author reply 208-10. PubMed ID: 18230281
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.